Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, with no bonus shares issued[5] - A cash dividend of CNY 2.5 per 10 shares was distributed, totaling approximately CNY 1.04 billion, which is 175.51% of the net profit for 2023[57] - The company plans to distribute a cash dividend of CNY 5 per 10 shares for the 2024 fiscal year, totaling around CNY 2.03 billion[57] - The total cash dividend, including other methods such as share buybacks, amounted to 438,236,334.87 CNY, representing 100% of the total distributable profit of 1,529,141,179.64 CNY[166] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the last fiscal year[15] - The company's operating revenue for 2024 reached ¥2,135,559,372.81, representing a 39.29% increase compared to ¥1,533,121,281.80 in 2023[21] - Net profit attributable to shareholders for 2024 was ¥356,803,430.03, a significant increase of 505.16% from ¥58,972,461.01 in 2023[21] - The net profit after deducting non-recurring gains and losses was ¥285,403,513.61, reflecting a 2,603.93% increase from ¥10,555,124.81 in 2023[21] - The net cash flow from operating activities for 2024 was ¥442,300,420.61, up 498.58% from ¥73,861,966.30 in 2023[21] - Basic and diluted earnings per share for 2024 were both ¥0.86, marking a 514.29% increase from ¥0.14 in 2023[21] - The gross profit margin for the reporting period was 68.75%[54] Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in Southeast Asia, aiming for a 20% increase in market share by 2025[15] - New product development is underway, with three innovative medical devices expected to launch in Q3 2025, projected to contribute an additional 10% to annual revenue[15] - The company has successfully completed two strategic acquisitions in the past year, enhancing its product portfolio and distribution capabilities[15] - The company plans to leverage national policy directions and market trends to enhance its competitive capabilities and capitalize on procurement opportunities[34] - The company is committed to increasing its market share in artificial joint products, which are the fastest-growing segment in the orthopedic implant market[103] Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for the upcoming fiscal year, targeting advancements in minimally invasive surgical technologies[15] - Research and development investment reached ¥306,869,754.43 in 2024, an increase of 7.57% from ¥285,275,500.97 in 2023, representing 14.37% of total operating revenue[79] - The number of R&D personnel increased by 10.45% to 835 in 2024, while the proportion of R&D personnel to total staff slightly decreased to 18.54%[79] - The company has a complete and independent research and development system, with the ability to operate independently in the market[128] Risk Management - The company has identified key risks for future growth, including regulatory changes and supply chain disruptions, and has outlined mitigation strategies[5] - The company faces risks from industry policy changes, foreign business operations, and product development, and will adjust its strategies accordingly[108][109] Corporate Governance - The company has established a "Quality and Return Improvement" action plan to enhance corporate governance and investor communication[114] - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[119] - The board of directors consists of 7 members, including 3 independent directors, complying with the requirements of the China Securities Regulatory Commission[121] - The company has established various internal systems for information disclosure, ensuring compliance with relevant laws and regulations[126] Environmental Responsibility - The company is committed to environmental protection and sustainable development, advocating for resource conservation and low pollution practices in its operations[195] - The company has implemented measures to ensure that all emissions are within the required standards, with no exceedances reported[188] - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[189] Employee Management - The company has a competitive salary policy, ensuring that at least 20% of the distributable profits are allocated for cash dividends if conditions are met[161] - The company has implemented a stock option incentive plan to enhance employee motivation and align interests with shareholders[158] - The company has a structured training program aimed at developing talent and ensuring a smooth integration of new employees[159] Shareholder Relations - The company emphasizes the importance of intellectual property rights, which are crucial for maintaining competitive advantage in the orthopedic medical device market[110] - The company is committed to improving information disclosure quality and strengthening investor relations to promote long-term sustainable development[116] - The company has accumulated cash dividends of approximately 311 million yuan from 2021 to 2023, accounting for about 37.66% of the net profit attributable to shareholders during the same period[115]

大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗68.26232.804.34137.29亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.24 ...

证券之星消息，截至2025年4月14日收盘，大博医疗(002901)报收于34.68元，上涨2.15%，换手率 0.73%，成交量2.1万手，成交额7306.51万元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-04-14 | 34.68 | 2.15% | 372.74万 | 5.10% | 531.54万 | 7.27% | -904.27万 | -12.38% | | 2025-04-11 | | 33.95 0.59% | -181.89万 | -3.72% | 310.05万 | 6.34% | -128.16万 | -2.62% | | 2025-04-10 | 33.75 | 2.43% | 103.71万 | 1.57% | -229.46万 | -3.47% | 125.75万 | 1.90% | | 2025-04-09 | | 32.95 -0.42% | 7.48万 | 0.09% ...

4月10日，大博医疗今日收盘33.75元，上涨2.43%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到69.47倍，总市值139.73亿元。 大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗69.47236.944.42139.73亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1硕世生物-1773.70-1773.701.1136.64亿2诺唯 赞-508.88-508.882.3392.08亿3博晖创新-340.62-209.723.7552.28亿4康泰医学-270.0231.682.7652.52亿5华 大基因-198.46217.092.05201.67亿6奥精 ...

证券代码：002901 证券简称：大博医疗 公告编号：2025-012 大博医疗科技股份有限公司 2025 年第一次临时股东大会决议公告 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2025 年 4 月 9 日（星期三）下午 14:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 9 日上 午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ①通过深圳证券交易所互联网投票系统投票的开始时间为 2025 年 4 月 9 日 上午 9:15 至下午 15:00 期间的任意时间。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 2、现场会议股东出席情况 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 1 5、现场会议地点： 厦门市海沧 ...

福建天衡联合律师事务所 关于大博医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 中国﹒厦门 厦禾路 666 号海翼大厦 A 幢 16-18 楼 厦门·上海·福州·泉州·龙岩 http://www.tenetlaw.com 福建天衡联合律师事务所 法律意见书 关于大博医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：大博医疗科技股份有限公司 根据中国证券监督管理委员会发布的《上市公司股东会规则》（以下简称《股 东会规则》）的要求，福建天衡联合律师事务所（以下简称"本所"）接受大博 医疗科技股份有限公司（以下简称"大博医疗"或"公司"）的委托，指派律师 （以下简称"本所律师"）出席大博医疗 2025 年第一次临时股东大会（以下简 称"本次股东大会"），对本次股东大会的召集与召开程序、出席会议人员与召 集人的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称《证券法》）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法 ...

最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗73.73251.484.69148.30亿行业平均 46.8850.714.88109.12亿行业中值33.6731.142.5548.71亿1硕世生物-1962.70-1962.701.2340.55亿2诺唯 赞-584.37-584.372.5299.35亿3博晖创新-304.96-187.763.3646.81亿4康泰医学-300.3935.243.0758.42亿5华 大基因-218.02238.482.25221.55亿6奥精医疗-121.72-121.721.5522.05亿7睿昂基因-85.04-85.041.3212.30亿 8热景生物-57.32-57.323.15102.74亿9华大智造-55.67-55.674.18333.50亿10中红医疗-54.71-37.220.8748.71 亿11天智航-47.01-47.014.9157.88亿 来源：金融界 4月2日，大 ...

证券之星消息，截至2025年3月31日收盘，大博医疗(002901)报收于34.54元，上涨0.49%，换手率 0.92%，成交量2.64万手，成交额9062.63万元。 3月31日的资金流向数据方面，主力资金净流入462.14万元，占总成交额5.1%，游资资金净流入419.09 万元，占总成交额4.62%，散户资金净流出881.22万元，占总成交额9.72%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-03-31 | 34.54 | 0.49% | 462.14万 | 5.10% | 419.09万 | 4.62% | -881.22万 | -9.72% | | 2025-03-28 | 34.37 | 1.87% | ● 340.12万 | 3.70% | 561.19万 | 6.11% | -901.30万 | -9.81% | | 2025-03-27 | 33.74 | ...

截至2025年3月28日收盘，大博医疗（002901）报收于34.37元，较上周的32.7元上涨5.11%。本周，大 博医疗3月28日盘中最高价报34.86元。3月24日盘中最低价报31.91元。大博医疗当前最新总市值142.3亿 元，在医疗器械板块市值排名17/124，在两市A股市值排名1127/5139。 大博医疗科技股份有限公司董事会提名魏志华为第三届董事会独立董事候选人，魏志华已通过资格审 查，符合相关法律法规对独立董事的要求。 关于补选第三届董事会独立董事的公告 独立董事王艳艳女士和林琳女士因连续担任公司独立董事满6年，申请辞去独立董事及董事会相关专门 委员会的职务。公司提名魏志华先生和林红珍女士为第三届董事会独立董事候选人。 本周关注点 公司公告汇总第三届董事会第十五次会议决议公告 大博医疗科技股份有限公司第三届董事会第十五次会议于2025年3月24日召开，审议通过以下议案：- 审议通过《关于补选第三届董事会独立董事的议案》，提名魏志华先生和林红珍女士为独立董事候选 人。- 审议通过《关于2025年度公司申请银行综合授信额度的议案》，拟申请不超过190,000万元人民币 的综合授信额度。- 审议通 ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.22倍，行业中值32.57倍，大博医疗排 名第103位。 截至2024年三季报，共有45家机构持仓大博医疗，其中基金45家，合计持股数581.00万股，持股市值 1.79亿元。 大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗70.75241.304.50142.30亿行业平均 45.2249.254.85107.95亿行业中值32.5731.042.4948.28亿1硕世生物-1928.41-1928.411.2139.84亿2诺唯 赞-570.10-570.102.4696.93亿3博晖创新-299.11-184.163.3045.91亿4康泰医学-292.1334.272.9 ...